CinRx Pharmaceuticals, LLC is a privately held, virtual biotech dedicated to repurposing existing molecules in a way that provides a clinically meaningful benefits to patients by enhancing safety or efficacy. Primarily focused 505(b)2 regulatory pathway, CinRx leverages the know-how of the world’s leading formulation and technology experts with exceptional medical expertise to create new opportunities for current therapeutics. The organization has a current portfolio in oncology, dermatology, and GI disorders. CinRx’s unique clinical development model allows flexibility in bringing repurposed drugs to market. A long-standing relationship with Medpace, Inc., a global Contract Research Organization (CRO) with operations in over 50 countries, allows the clinical development to progress in a highly efficient, cost-effective manner. The Medpace-CinRx alliance offers a competitive advantage to comprehensive drug development.